Award
National Cancer Institute 5R01CA281295-04
KRAS G12C: Kinetic and Redox Characterization of Covalent Inhibition
Recipient
University of North Carolina at Chapel Hill, Department of Biochemistry
Award Amount
$569,072.00
Ceiling
$569,072.00
Awarded
March 19, 2026
Identifier
5R01CA281295-04
Research project funded by the National Cancer Institute to study the kinetics and redox effects of KRAS G12C covalent inhibitors, aiming to improve understanding of drug resistance in cancer therapy.
Description
This project focuses on targeted cancer therapy development, specifically KRAS G12C inhibitors, and investigates resistance mechanisms involving redox modifications. It aims to elucidate the kinetic mechanisms of these inhibitors, investigate redox sensitivity and oxidative modifications of KRASG12C, and explore resistance mechanisms related to redox modifications.